BioMotiv and Bristol-Myers Squibb company together announced the launch of new Anteros Pharmaceuticals
Bristol-Myers Squibb Company and BioMotiv, an accelerator company, associated with The Harrington Project for discovery and development of therapeutics today, announced the launch of Anteros Pharmaceuticals.
Anteros Pharmaceuticals is a biotechnology company focused on developing new drugs for inflammatory and fibrotic diseases.
Yale University first developed the intellectual property behind Anteros. Bristol-Myers Squibb in-licensed initially and subsequently assigned to Anteros. Since executing the Strategic Partnership Agreement between BioMotiv and Bristol-Myers Squibb, this is the first company they have launched.
According to the agreement, Bristol-Myers Squibb will provide data, IP, and reagents for a group of molecules against an undisclosed mechanism and BioMotiv in association with Yale will solely be responsible for research and development.
Bristol-Myers Squibb has the option to acquire the company from BioMotiv under pre-agreed terms provided Anteros nominates a pre-clinical candidate
Anteros Pharmaceuticals is the first company to launch among the several companies Bristol-Myers Squibb and BioMotiv plan to form. Anteros will focus on developing a new class of drugs for inflammatory diseases that affect millions of patients and about which not much is known.
“Our broader mission is to translate novel discoveries into breakthrough
therapies for patients in need, forming companies such as Anteros to achieve this goal,” said Satish Jindal, Ph.D., BioMotiv’s CEO.About BioMotiv
BioMotiv is an accelerator company associated with a $340 million UK and US initiative focused on accelerating early-stage breakthrough discoveries into medicines, the Harrington Project. BioMotiv is led by a highly passionate and accomplished team of veteran biopharma experts.
About Bristol-Myers Squibb
To discover, develop, and deliver new classes of medicines that could help patients to overcome serious illnesses is the mission of Bristol-Myers Squibb, which is a global pharmaceutical company. Juno Therapeutics and Celgene are Bristol-Myers Squibb Company’s wholly-owned subsidiaries.
